Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome.

Published

Journal Article (Review)

Long QT syndrome (LQTS) is one of several primary electrical disorders or hereditary arrhythmia syndromes along with the short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Since its initial recognition in 1957 by Jervell and Lange-Nielsen (Am Heart J. 1957;54:59-68), LQTS has been intimately associated with risk for sudden cardiac death. The implantable defibrillator was developed by Morowski et al (N Engl J Med. 1980;303:322-4) as a treatment to prevent sudden cardiac death. Consequently, implanted cardioverter-defibrillator therapy deserves serious consideration as an important therapy for LQTS.

Full Text

Duke Authors

Cited Authors

  • Daubert, JP; Zareba, W; Rosero, SZ; Budzikowski, A; Robinson, JL; Moss, AJ

Published Date

  • April 2007

Published In

Volume / Issue

  • 153 / 4 Suppl

Start / End Page

  • 53 - 58

PubMed ID

  • 17394903

Pubmed Central ID

  • 17394903

Electronic International Standard Serial Number (EISSN)

  • 1097-6744

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2007.01.025

Language

  • eng

Conference Location

  • United States